Impact of cardiac stem cell sheet transplantation on myocardial infarction

Abstract

The 3-layered cell-sheet improved cardiac function associated with angiogenic and anti-fibrotic effects. Thus, CSC is a promising cell-source to use with the cell-sheet method for the treatment of cardiac failure, as long as a sufficient number of cells are delivered.

Human Cardiac Stem Cells With Reduced Notch Signaling Show Enhanced Therapeutic Potential in a Rat Acute Infarction Model

“…This xenotransplantation model has been used in a number of studies, which have rarely reported significant immunological reactions. 22, 35 In fact, the transplanted cells in this study were not histologically involved in inflammatory reactions such as accumulation of inflammatory cells (data not shown). Thus, immune rejection in this model is minimal and does not affect the results.…”

Apelinergic system in endothelial cells and its role in angiogenesis in myocardial ischemia

“…Nevertheless, the outcomes of clinical studies on stem cell transplantation vary and point to little long-term benefit [130]. New approaches are therefore being applied in experimental models, including cell-sheet transplantation [131,132], gene modification of stem cells [11,133], and co-delivery of stem cells with pro-angiogenic growth factors [13]. Recently, apelin, a critical enhancer of angiogenesis, was reported to be reduced in patients after MI [20] while lower apelin level had an inhibitory effect on vascular sprouting and myocardial angiogenesis [20].…”

Stem cell-derived cell sheet transplantation for heart tissue repair in myocardial infarction

“…The cell sources for sheet used in cardiac transplantation to damaged hearts with MI in animal models include fibroblasts [33,34], endothelial cells [35], cardiomyocytes cocultured with endothelial cells [35], dermal fibroblasts cocultured with endothelial progenitor cells [33], SMs [36][37][38][39][40][41], mesenchymal stem cells from adipose tissue [42,43], bone marrow [44,45], menstrual blood [46], adipocytes [47], adipose-derived stem cells [42,43], cardiomyocytes from neonatal animals [34], Sca-1 (+) CPCs and Ckit (+) CPCs from adult murine hearts [48,49], and ESC/ iPSC-derived pure cardiomyocytes [50] or multiple cardiac cell lineages composed of cardiomyocytes and vascular cells [51,52]. Collectively, considering their benefits and further perspectives of clinical application, we reviewed research updates about the use of SM-, MSC-, and ESC/ iPSC-CM-derived cell sheet in MI therapy in this current paper.…”